
Baillie Gifford China Growth Trust plc 05
Strategic Report
As noted above, the opportunities within China have remained
remarkably consistent. But so have the risks. This is an asset
class in which drawdowns and periods of market volatility are
the norm rather than the exception. Indeed, the propensity for
volatility has likely been heightened by the increasingly competitive
relationship between China and the US, and tensions with Taiwan
as noted more fully in our Interim Management Report published
in October 2022. As such, this remains an asset class with big
risks and big opportunities, and one that is only suitable for those
with the appropriate risk tolerance and long-term time horizon.
Portfolio Positioning and Recent Activity
The current portfolio represents a selection of the best and most
innovative public and private Chinese growth companies. As one
would expect for a long-term growth manager, the themes that
we are excited about within the Company remain largely
consistent with those discussed in last year’s Managers’ Report.
These include our investments in companies exposed to the
green revolution both in China and abroad; companies that
contribute to China’s ambition to advance its manufacturing
capabilities in robotics and automation; ‘little giants’ that have
developed significant expertise in relatively niche but strategically
important industries such as semiconductors; software related
companies that are helping traditional industries upgrade; leading
domestic brands that have the scope to challenge foreign brands
within China and abroad; long duration growth companies within
the platform economy that continue to add value to consumers’
lives; in short, companies that we believe at the broadest level are
likely to contribute to China’s economic, societal and
environmental development over the next decade.
In terms of new purchases, we bought holdings in Centre Testing
and Dongguan Yiheda, both of which are contributing to the
upgrading of traditional industries in China. Centre Testing is
a company that provides testing, inspection and certification
services to a broad range of companies and industries. Our first
in-depth report on the company was written in early 2020. Whilst
we admired the growth potential of the business and the quality of
the management team, we were less convinced by the valuation.
Since then, the shares have substantially de-rated providing us
with a good opportunity to make an attractive investment. Centre
Testing is a leading private player within an industry dominated
by state-owned enterprises and foreign companies. It has a scale
and reputation advantage over smaller domestic competitors
and a service edge over global companies and state-owned-
enterprises. This should allow it to take share. It is also able
to supplement this organic growth via acquisitions of smaller
competitors in new verticals. As such, we believe it is likely to
grow at a double-digit rate for a very long time, an outcome that
is not reflected in the current valuation.
Dongguan Yiheda makes a wide variety of parts used in factory
automation equipment. It offers a product catalogue to design
engineers of non-standard, customisable parts. It then
manufacturers these parts quickly and at scale thereby saving
time and reducing costs for its design engineer customers. The
opportunity for Yiheda is to increase the number and type of parts
it offers within its catalogue and thereby gain a greater share
of wallet within factory automation equipment. The overall
addressable market in machine parts is large and growing and the
founder believes it can treble its share. The growth runway for the
company is therefore very long and the business itself is profitable
and cash generative.
As noted in our Interim Report, we also made investments in
Jiangsu Azure, a leading small form battery maker in the power
tools market, and Kinlong, a hardware provider to the building
industry. For Jiangsu Azure, the electrification of the power tools
market is a strong structural growth driver, whilst the company
also has longer term opportunities in batteries for vacuum
cleaners and e-bikes. Its focus on these relatively niche markets
and its willingness to invest also gives it scope to take further
share from global competitors such as LG and Samsung. Kinlong
has a strong reputation for quality amongst its building industry
customers. It is the number one player in a number of the segments
in which it operates with c.10% share. Its growth opportunity is a
function of continued growth in end markets, the expansion of its
product portfolio, and continued market share gains. This is
another good quality, long-term growth company that we were
able to buy at a time of share price weakness.
We have also made additions to a number of stocks throughout
the year on valuation grounds. These include Alibaba, China’s
leading ecommerce business; KE Holdings, an online real estate
portal; China Merchant’s Bank, China’s leading wealth
management and high-end banking business; and Ping An Bank,
a leading retail bank and part of the Ping An group of companies.
In order to fund the above, we sold a number of our lower
conviction, smaller holdings. These include both Tencent Music
and Bilibili. Tencent Music was bought due to its potential in
on-demand music streaming. However, both the regulatory
backdrop and the competitive environment deteriorated markedly
post-purchase. The regulator’s anti-monopoly ruling impacted the
viability of Tencent Music’s exclusivity contracts with labels and
has made it much easier for competitors to add popular songs to
their portals. ByteDance has also entered the market and is
increasingly seen as a platform via which new artists can be
incubated. As such, we believe the company’s growth outlook
and longer term profitability are likely to be lower than we initially
thought and that investment returns from here are unlikely to be
attractive. Bilibili is a media and entertainment company popular
with generation Z. We sold the holding during the period due to
unexpectedly strong competition from ByteDance and Kuaishou,
and markedly weaker operational performance as a result. The
company appeared overly reliant on subsidies for growth and as
such we became less convinced by its long-term business model.
In the healthcare space, we sold BGI, Zai Labs, and Hutchison
China Meditech, partly due to weaker than expected operational
performance, and partly to reduce our healthcare overweight
given concerns around sanctions risk within this sector. We also
sold small holdings in Lufax, an SME lender, and Yatsen, a
cosmetics company.